Lung Cancer | Specialty

Dr. Patel on the Role of Immunotherapy Combinations in Lung Cancer

November 2nd 2020

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

ADAURA Generates Excitement for Targeted Therapy in Adjuvant EGFR+ NSCLC

November 2nd 2020

Balazs Halmos, MD, MS, highlights the significance of the ADAURA trial in EGFR-positive NSCLC, questions raised by these data, and other efforts being made in the adjuvant setting.

Research Efforts Strive to Overcome Osimertinib Resistance in EGFR+ Lung Cancer

November 2nd 2020

Helena A. Yu, MD, discusses novel non–small cell lung cancer combinations and biomarkers that are under investigation in order to overcome osimertinib resistance

FDA Approves First Companion Diagnostic for Expanded EGFR TKIs in NSCLC

October 30th 2020

The FDA has approved the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of patients with EGFR-mutated non–small cell lung cancer.

Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC

October 30th 2020

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

October 29th 2020

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Raez on the Rise of Liquid Biopsy in Lung Cancer

October 29th 2020

In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.

FDA Grants Priority Review to Cemiplimab for Advanced NSCLC With High PD-L1 Expression

October 29th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer with a PD-L1 expression of 50% or greater.

Martins Makes Sense of the Complicated Frontline NSCLC Treatment Landscape

October 29th 2020

Renato G. Martins, MD, discusses the many up-front approaches that have emerged in NSCLC, remaining questions to address with future efforts, and novel combinations under exploration.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

Targeted Therapy Research Booms in Biomarker-Positive NSCLC

October 28th 2020

Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level.

Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC

October 28th 2020

Christina Baik, MD, MPH, highlights the evolving role of EGFR inhibition in the NSCLC space.

Pralsetinib and Selpercatinib Expand the RET+ NSCLC Paradigm

October 27th 2020

Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non–small cell lung cancer who harbor RET rearrangements.

Adagrasib Shows Early Activity in KRAS G12C+ NSCLC, CRC, and Other Solid Tumors

October 26th 2020

Adagrasib, a potent and selective inhibitor of KRAS G12C, showcased encouraging clinical activity with an acceptable safety profile in patients with KRAS G12C–positive non–small cell lung cancer, colorectal cancer, and other solid tumors.

Takeaways on Treatment of Early-Stage NSCLC

October 26th 2020

The Future of Lung Cancer Treatment

October 26th 2020

Mesothelioma: A Look at DREAM3R and PrECOG Trial

October 26th 2020

Risk of Pneumonitis Post-Chemoradiation in Stage 3 NSCLC

October 26th 2020

Fundamentals of Mesothelioma

October 26th 2020

Considering PD-L1 and EGFR Status With I/O in Stage 3 NSCLC

October 26th 2020